LLY vs. REGN: A Head-to-Head Stock Comparison

Updated on October 7, 2025

Here’s a clear look at LLY and REGN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	LLY	REGN
Company Name	Eli Lilly and Company	Regeneron Pharmaceuticals, Inc.
Country	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Biotechnology
Market Capitalization	752.91 billion USD	63.59 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	June 1, 1972	April 2, 1991
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of LLY and REGN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

LLY vs. REGN: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	LLY	REGN
5-Day Price Return	15.60%	7.00%
13-Week Price Return	7.58%	9.62%
26-Week Price Return	1.69%	-5.40%
52-Week Price Return	-5.75%	-42.32%
Month-to-Date Return	10.07%	6.71%
Year-to-Date Return	8.79%	-15.77%
10-Day Avg. Volume	4.54M	1.22M
3-Month Avg. Volume	4.24M	1.15M
3-Month Volatility	45.17%	30.81%
Beta	0.37	0.37

Profitability

Return on Equity (TTM)

LLY

88.36%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

REGN

15.11%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, REGN’s Return on Equity of 15.11% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

LLY vs. REGN: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

LLY

25.91%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

REGN

31.37%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

A Net Profit Margin of 31.37% places REGN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.

LLY vs. REGN: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

LLY

32.37%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

REGN

27.02%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

An Operating Profit Margin of 27.02% places REGN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

LLY vs. REGN: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	LLY	REGN
Return on Equity (TTM)	88.36%	15.11%
Return on Assets (TTM)	16.02%	11.81%
Net Profit Margin (TTM)	25.91%	31.37%
Operating Profit Margin (TTM)	32.37%	27.02%
Gross Profit Margin (TTM)	82.64%	86.46%

Financial Strength

Current Ratio (MRQ)

LLY

1.28

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

REGN

4.60

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

REGN’s Current Ratio of 4.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

LLY vs. REGN: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

LLY

2.18

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

With a Debt-to-Equity Ratio of 2.18, LLY operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

REGN

0.09

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

REGN’s Debt-to-Equity Ratio of 0.09 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

LLY vs. REGN: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

LLY

20.36

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

REGN

243.95

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

With an Interest Coverage Ratio of 243.95, REGN demonstrates a superior capacity to service its debt, placing it well above the typical range for the Biotechnology industry. This stems from either robust earnings or a conservative debt load.

LLY vs. REGN: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	LLY	REGN
Current Ratio (MRQ)	1.28	4.60
Quick Ratio (MRQ)	0.53	3.78
Debt-to-Equity Ratio (MRQ)	2.18	0.09
Interest Coverage Ratio (TTM)	20.36	243.95

Growth

Revenue Growth

LLY vs. REGN: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

LLY vs. REGN: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

LLY

0.65%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

LLY’s Dividend Yield of 0.65% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

LLY vs. REGN: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

LLY

36.46%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

REGN

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

REGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

LLY vs. REGN: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	LLY	REGN
Dividend Yield (TTM)	0.65%	0.00%
Dividend Payout Ratio (TTM)	36.46%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

LLY

56.49

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

At 56.49, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

REGN

14.29

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

In the lower quartile for the Biotechnology industry, REGN’s P/E Ratio of 14.29 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

LLY vs. REGN: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

LLY

14.64

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

With a P/S Ratio of 14.64, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

REGN

4.48

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

REGN’s P/S Ratio of 4.48 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

LLY vs. REGN: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

LLY

40.43

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

REGN

1.89

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

REGN’s P/B Ratio of 1.89 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

LLY vs. REGN: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	LLY	REGN
Price-to-Earnings Ratio (TTM)	56.49	14.29
Price-to-Sales Ratio (TTM)	14.64	4.48
Price-to-Book Ratio (MRQ)	40.43	1.89
Price-to-Free Cash Flow Ratio (TTM)	387.91	17.92